Epigenetic mechanisms in schizophrenia

Dialogues in Clinical Neuroscience

Volumn 16, Issue 3, 2014, Pages 405-417

  Akbarian, Schahram ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

DNA methylation; Epigenetic drug target; Epigenome; Histone modification; Prefrontal cortex; Psychosis

Indexed keywords

ARTICLE; DNA METHYLATION; EPIGENETICS; FUNCTIONAL GENOMICS; GENE MAPPING; GENETIC RISK; GENOTYPE ENVIRONMENT INTERACTION; HISTONE MODIFICATION; HUMAN; NEUROPATHOLOGY; NONHUMAN; REGULATORY MECHANISM; SCHIZOPHRENIA; ANIMAL; GENETIC EPIGENESIS; GENETICS; METABOLISM; PATHOLOGY; PHYSIOLOGY; PREFRONTAL CORTEX;

ANIMALS; EPIGENESIS, GENETIC; EPIGENOMICS; HUMANS; PREFRONTAL CORTEX; SCHIZOPHRENIA;

EID: 84911397798     PISSN: 12948322     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (149)

1. Hennekens CH, Hennekens AR, Hollar D, Casey DE. Schizophrenia and increased risks of cardiovascular disease. Am Heart J. 2005;150:1115-1121.
2. Laursen TM, Munk-Olsen T, Vestergaard M. Life expectancy and cardiovascular mortality in persons with schizophrenia. Curr Opin Psychiatry. 2012;25:83-88.
3. Saha S, Chant D, McGrath J. A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time? Arch Gen Psychiatry. 2007;64:1123-1131.
4. Taly A. Novel approaches to drug design for the treatment of schizophrenia. Exp Opin Drug Discovery.2013;8:1285-1296.
5. Kim DH, Stahl SM. Antipsychotic drug development. Curr Topics Behav Neurosci. 2010;4:123-139.
6. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353:1209-1223.
7. Swartz MS, Perkins DO, Stroup TS, et al. Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study. Am J Psychiatry. 2007;164:428-436.
8. Ibrahim HM, Tamminga CA. Schizophrenia: treatment targets beyond monoamine systems. Annu Rev Pharmacol Toxicol. 2011;51:189-209.
9. Catts VS, Fung SJ, Long LE, et al. Rethinking schizophrenia in the context of normal neurodevelopment. Front Cell Neurosci. 2013;7:60.
10. Dorph-Petersen KA, Lewis DA. Stereological approaches to identifying neuropathology in psychosis. Biol Psychiatry. 2011;69:113-126.
11. Andreassen OA, Thompson WK, Dale AM. Boosting the power of schizophrenia genetics by leveraging new statistical tools. Schizophr Bull. 2014;40:13-17.
12. Rodriguez-Murillo L, Gogos JA, Karayiorgou M. The genetic architecture of schizophrenia: new mutations and emerging paradigms. Annu Rev Med. 2012;63:63-80.
13. Sweatt JD. The emerging field of neuroepigenetics. Neuron. 2013;80:624-632.
14. Akbarian S, Nestler EJ. Epigenetic mechanisms in psychiatry. Neuropsychopharmacology. 2013;38:1-2.
15. Sweatt JD. Epigenetic Regulation in the Nervous System: Basic Mechanisms and Clinical Impact. London, UK; Waltham, MA: Academic Press; 2013.
16. Petronis A, Mill J. Brain, Behavior, and Epigenetics. Berlin, Heidelberg, Germany: Springer; 2011.
17. Appasani K. Epigenomics, from Chromatin Biology to Therapeutics. Cambridge, UK; New York, NY: Cambridge University Press; 2012.
18. Schroeder FA, Chonde DB, Riley MM, et al. FDG-PET imaging reveals local brain glucose utilization is altered by class I histone deacetylase inhibitors. Neurosci Lett. 2013;550:119-124.
19. Kurita M, Holloway T, Garcia-Bea A, et al. HDAC2 regulates atypical antipsychotic responses through the modulation of mGlu2 promoter activity. Nat Neurosci. 2012;15:1245-1254.
20. Abel T, Zukin RS. Epigenetic targets of HDAC inhibition in neurodegenerative and psychiatric disorders. Curr Opin Pharmacol. 2008;8:57-64.
21. Vecsey CG, Hawk JD, Lattal KM, et al. Histone deacetylase inhibitors enhance memory and synaptic plasticity via CREB:CBP-dependent transcriptional activation. J Neurosci. 2007;27:6128-6140.
22. Jakovcevski M, Akbarian S. Epigenetic mechanisms in neurological disease. Nat Med 2012;18:1194-1204.
23. Bohacek J, Gapp K, Saab BJ, Mansuy IM. Transgenerational epigenetic effects on brain functions. Biol Psychiatry. 2013;73:313-320.
24. Rodriguez-Paredes M, Esteller M. Cancer epigenetics reaches mainstream oncology. Nat Med. 2011;17:330-339.
25. Li G, Reinberg D. Chromatin higher-order structures and gene regulation. Curr Opin Genet Dev. 2011;21:175-186.
26. Zhou VW, Goren A, Bernstein BE. Charting histone modifications and the functional organization of mammalian genomes. Nat Rev Genetics. 2011;12:7-18.
27. Ederveen TH, Mandemaker IK, Logie C. The human histone H3 complement anno 2011. Biochim Biophys Acta. 2011;1809:577-586.
28. Kinney SM, Chin HG, Vaisvila R, et al. Tissue-specific distribution and dynamic changes of 5-hydroxymethylcytosine in mammalian genomes. J Biol Chem. 2011;286:24685-24693.
29. Kriaucionis S, Heintz N. The nuclear DNA base 5-hydroxymethylcytosine is present in Purkinje neurons and the brain. Science. 2009;324:929-930.
30. Jin SG, Wu X, Li AX, Pfeifer GP. Genomic mapping of 5-hydroxymethylcytosine in the human brain. Nucleic Acids Res. 2011;39:5015-5024.
31. Song CX, Szulwach KE, Fu Y, et al. Selective chemical labeling reveals the genome-wide distribution of 5-hydroxymethylcytosine. Nat Biotechnol. 2011;29:68-72.
32. Maunakea AK, Nagarajan RP, Bilenky M, al. Conserved role of intragenic DNA methylation in regulating alternative promoters. Nature. 2010;466:253-257.
33. Sharma RP, Grayson DR, Guidotti A, Costa E. Chromatin, DNA methylation and neuron gene regulation--the purpose of the package. J Psychiatry Neurosci. 2005;30:257-263.
34. Tan M, Luo H, Lee S, J et al. Identification of 67 histone marks and histone lysine crotonylation as a new type of histone modification. Cell. 2011;146:1016-1028.
35. Kouzarides T. Chromatin modifications and their function. Cell. 2007;128:693-705.
36. Taverna SD, Li H, Ruthenburg AJ, Allis CD, Patel DJ. How chromatinbinding modules interpret histone modifications: lessons from professional pocket pickers. Nat Struct Mol Biol. 2007;14:1025-1040.
37. Mosammaparast N, Shi Y. Reversal of histone methylation: biochemical and molecular mechanisms of histone demethylases. Annu Rev Biochem. 2010;79:155-179.
38. Justin N, De Marco V, Aasland R, Gamblin SJ. Reading, writing and editing methylated lysines on histone tails: new insights from recent structural studies. Curr Opin Struct Biol. 2010: 730-738.
39. Jin C, Felsenfeld G. Nucleosome stability mediated by histone variants H3.3 and H2A.Z. Genes Dev. 2007;21:1519-1529.
40. Jin F, Li Y, Dixon JR, et al. A high-resolution map of the three-dimensional chromatin interactome in human cells. Nature. 2013;503:290-294.
41. Martins-de-Souza D, Gattaz WF, Schmitt A, et al. Alterations in oligodendrocyte proteins, calcium homeostasis and new potential markers in schizophrenia anterior temporal lobe are revealed by shotgun proteome analysis. J Neural Transm. 2009;116:275-289.
42. Regenold WT, Phatak P, Marano CM, Gearhart L, Viens CH, Hisley KC. Myelin staining of deep white matter in the dorsolateral prefrontal cortex in schizophrenia, bipolar disorder, and unipolar major depression. Psychiatry Res. 2007;151:179-188.
43. Katsel P, Davis KL, Haroutunian V. Variations in myelin and oligodendrocyte-related gene expression across multiple brain regions in schizophrenia: a gene ontology study. Schizophr Res. 2005;79:157-173.
44. Aston C, Jiang L, Sokolov BP. Microarray analysis of postmortem temporal cortex from patients with schizophrenia. J Neurosci Res. 2004;77:858-866.
45. Hakak Y, Walker JR, Li C, et al. Genome-wide expression analysis reveals dysregulation of myelination-related genes in chronic schizophrenia. Proc Natl Acad Sci U S A. 2001;98:4746-4751.
46. Tkachev D, Mimmack ML, Ryan MM, et al. Oligodendrocyte dysfunction in schizophrenia and bipolar disorder. Lancet. 2003;362:798-805.
47. Duncan CE, Webster MJ, Rothmond DA, Bahn S, Elashoff M, Shannon Weickert C. Prefrontal GABA(A) receptor alpha-subunit expression in normal postnatal human development and schizophrenia. J Psychiatr Res. 2010:44:673-681.
48. Charych EI, Liu F, Moss SJ, Brandon NJ. GABA(A) receptors and their associated proteins: implications in the etiology and treatment of schizophrenia and related disorders. Neuropharmacology. 2009;57:481-495.
49. Woo TU, Kim AM, Viscidi E. Disease-specific alterations in glutamatergic neurotransmission on inhibitory interneurons in the prefrontal cortex in schizophrenia. Brain Res. 2008;1218:267-277.
50. Akbarian S, Huang HS. Molecular and cellular mechanisms of altered GAD1/GAD67 expression in schizophrenia and related disorders. Brain Res Rev. 2006;52:293-304.
51. Guidotti A, Auta J, Davis JM, et al. GABAergic dysfunction in schizophrenia: new treatment strategies on the horizon. Psychopharmacology. 2005;180:191-205.
52. Dracheva S, Elhakem SL, McGurk SR, Davis KL, Haroutunian V. GAD67 and GAD65 mRNA and protein expression in cerebrocortical regions of elderly patients with schizophrenia. J Neurosci Res. 2004;76:581-592.
53. Hashimoto T, Bazmi HH, Mirnics K, Wu Q, Sampson AR, Lewis DA. Conserved regional patterns of GABA-related transcript expression in the neocortex of subjects with schizophrenia. Am J Psychiatry. 2008;165:479-489.
54. Benes FM. Amygdalocortical circuitry in schizophrenia: from circuits to molecules. Neuropsychopharmacology. 2010;35:239-257.
55. Beneyto M, Kristiansen LV, Oni-Orisan A, McCullumsmith RE, Meador-Woodruff JH. Abnormal glutamate receptor expression in the medial temporal lobe in schizophrenia and mood disorders. Neuropsychopharmacology. 2007;32:1888-1902.
56. Meador-Woodruff JH, Healy DJ. Glutamate receptor expression in schizophrenic brain. Brain Res Rev. 2000;31:288-294.
57. Hemby SE, Ginsberg SD, Brunk B, Arnold SE, Trojanowski JQ, Eberwine JH. Gene expression profile for schizophrenia: discrete neuron transcription patterns in the entorhinal cortex. Arch Gen Psychiatry. 2002;59:631-640.
58. Mirnics K, Middleton FA, Marquez A, Lewis DA, Levitt P. Molecular characterization of schizophrenia viewed by microarray analysis of gene expression in prefrontal cortex. Neuron. 2000;28:53-67.
59. Middleton FA, Mirnics K, Pierri JN, Lewis DA, Levitt P. Gene expression profiling reveals alterations of specific metabolic pathways in schizophrenia. J Neurosci. 2002;22:2718-2729.
60. Vogel-Ciernia A, Wood MA. Neuron-specific chromatin remodeling: A missing link in epigenetic mechanisms underlying synaptic plasticity, memory, and intellectual disability disorders. Neuropharmacology. 2014;80:18-27.
61. Adachi M, Monteggia LM. Decoding transcriptional repressor complexes in the adult central nervous system. Neuropharmacology. 2014.80:45-52.
62. Abdolmaleky HM, Cheng KH, Russo A, et al. Hypermethylation of the reelin (RELN) promoter in the brain of schizophrenic patients: a preliminary report. Am J Med Genet B Neuropsychiatr Genet. 2005;134:60-66.
63. Grayson DR, Jia X, Chen Y, et al. Reelin promoter hypermethylation in schizophrenia. Proc Natl Acad Sci U S A. 2005;102:9341-9346.
64. Iwamoto K, Bundo M, Yamada K, et al. DNA methylation status of SOX10 correlates with its downregulation and oligodendrocyte dysfunction in schizophrenia. J Neurosci. 2005;25:5376-5381.
65. Tang B, Dean B, Thomas EA. Disease-and age-related changes in histone acetylation at gene promoters in psychiatric disorders. Transl Psychiatry. 2011;1:e64.
66. Huang HS, Matevossian A, Whittle C, et al. Prefrontal dysfunction in schizophrenia involves mixed-lineage leukemia 1-regulated histone methylation at GABAergic gene promoters. J Neurosci. 2007;27:11254-11262.
67. Aberg KA, McClay JL, Nerella S,et al. Methylome-Wide Association study of schizophrenia: identifying blood biomarker signatures of environmental insults. JAMA Psychiatry. 2014;71:255-264.
68. Gavin DP, Kartan S, Chase K, Jayaraman S, Sharma RP. Histone deacetylase inhibitors and candidate gene expression: An in vivo and in vitro approach to studying chromatin remodeling in a clinical population. J Psych Res. 2009;43:870-876.
69. Auta J, Smith RC, Dong E, et al. DNA-methylation gene network dysregulation in peripheral blood lymphocytes of schizophrenia patients. Schizophr Res. 2013;150:312-318.
70. Ikegame T, Bundo M, Murata Y, Kasai K, Kato T, Iwamoto K. DNA methylation of the BDNF gene and its relevance to psychiatric disorders. J Hum Genet. 2013;58:434-438.
71. Kano S, Colantuoni C, Han F, et al. Genome-wide profiling of multiple histone methylations in olfactory cells: further implications for cellular susceptibility to oxidative stress in schizophrenia. Mol Psychiatry. 2013;18:740-742.
72. Dempster EL, Pidsley R, Schalkwyk LC, et al. Disease-associated epigenetic changes in monozygotic twins discordant for schizophrenia and bipolar disorder. Hum Mol Genet. 2011;20:4786-4796.
73. Mill J, Tang T, Kaminsky Z, Khare T, et al. Epigenomic profiling reveals DNA-methylation changes associated with major psychosis. Am J Hum Genet. 2008;82:696-711.
74. Wockner LF, Noble EP, Lawford BR, et al. Genome-wide DNA methylation analysis of human brain tissue from schizophrenia patients. Transl Psychiatry. 2014;4:e339.
75. Rivera CM, Ren B. Mapping human epigenomes. Cell. 2013;155:39-55.
76. Zazzu V, Regierer B, Kuhn A, Sudbrak R, Lehrach H. IT Future of medicine: from molecular analysis to clinical diagnosis and improved treatment. New Biotechnol. 2013;30:362-365.
77. Elangovan RI, Disanto G, Berlanga-Taylor AJ, Ramagopalan SV, Handunnetthi L. Regulatory genomic regions active in immune cell types explain a large proportion of the genetic risk of multiple sclerosis. J Hum Genet. 2014;59:211-215.
78. Numata S, Ye T, Hyde TM, et al. DNA methylation signatures in development and aging of the human prefrontal cortex. Am J Hum Genet. 2012;90:260-272.
79. Zhang D, Cheng L, Badner JA, et al. Genetic control of individual differences in gene-specific methylation in human brain. Am J Hum Genet. 2010;86:411-419.
80. Schwab SG, Wildenauer DB. Genetics of psychiatric disorders in the GWAS era: an update on schizophrenia. Eur Arch Psychiatry Clin Neurosci. 2013;263(suppl 2):S147-S154.
81. Ripke S, O'Dushlaine C, Chambert K, et al. Genome-wide association analysis identifies 13 new risk loci for schizophrenia. Nat Genet. 2013;45:1150-1159.
82. Volman V, Behrens MM, Sejnowski TJ. Downregulation of parvalbumin at cortical GABA synapses reduces network gamma oscillatory activity. J Neurosci. 2011;31:18137-18148.
83. Curley AA, Lewis DA. Cortical basket cell dysfunction in schizophrenia. J Physiol. 2012;590(Pt 4):715-724.
84. Benes FM, Lim B, Matzilevich D, Walsh JP, Subburaju S, Minns M. Regulation of the GABA cell phenotype in hippocampus of schizophrenics and bipolars. Proc Natl Acad Sci U S A. 2007;104:10164-10169.
85. Guidotti A, Auta J, Davis JM, et al. Decrease in reelin and glutamic acid decarboxylase67 (GAD67) expression in schizophrenia and bipolar disorder: a postmortem brain study. Arch Gen Psychiatry. 2000;57:1061-1069.
86. Blatt GJ, Fatemi SH. Alterations in GABAergic biomarkers in the autism brain: research findings and clinical implications. Anat Rec. 2011;294:1646-1652.
87. Akbarian S, Kim JJ, Potkin SG, Hagman JO, Tafazzoli A, Bunney WE, Jr., et al. Gene expression for glutamic acid decarboxylase is reduced without loss of neurons in prefrontal cortex of schizophrenics. Arch Gen Psychiatry. 1995;52:258-266.
88. Addington AM, Gornick M, Duckworth J, Sporn A, Gogtay N, Bobb A, et al. GAD1 (2q31.1), which encodes glutamic acid decarboxylase (GAD67), is associated with childhood-onset schizophrenia and cortical gray matter volume loss. Mol Psychiatry. 2005;10:581-588.
89. Straub RE, Lipska BK, Egan MF, Goldberg TE, Kleinman JE, Weinberger DR. Allelic variation in GAD1 (GAD67) is associated with schizophrenia and influences cortical function and gene expression. Mol Psychiatry. 2007; 12:854-869.
90. Marenco S, Savostyanova AA, van der Veen JW, et al. Genetic modulation of GABA levels in the anterior cingulate cortex by GAD1 and COMT. Neuropsychopharmacology. 2010;35:1708-1717.
91. Bharadwaj R, Jiang Y, Mao W, et al. Conserved chromosome 2q31 conformations are associated with transcriptional regulation of GAD1 GABA synthesis enzyme and altered in prefrontal cortex of subjects with schizophrenia. J Neurosci. 2013;33:11839-11851.
92. Heck A, Fastenrath M, Ackermann S, et al. Converging genetic and functional brain imaging evidence links neuronal excitability to working memory, psychiatric disease, and brain activity. Neuron. 2014;81:1203-1213.
93. Meaney MJ. Epigenetics and the biological definition of gene x environment interactions. Child Dev. 2010;81:41-79.
94. Brown AS, Patterson PH. Maternal infection and schizophrenia: implications for prevention. Schizophr Bull. 2011;37:284-290.
95. Schmitt A, Malchow B, Hasan A, Falkai P. The impact of environmental factors in severe psychiatric disorders. Front Neurosci. 2014;8:19.
96. Siegmund KD, Connor CM, Campan M, et al. DNA methylation in the human cerebral cortex is dynamically regulated throughout the life span and involves differentiated neurons. PloS One. 2007;2:e895.
97. Shulha HP, Cheung I, Guo Y, Akbarian S, Weng Z. Coordinated cell type-specific epigenetic remodeling in prefrontal cortex begins before birth and continues into early adulthood. PLoS Genetics. 2013;9:e1003433.
98. Cheung I, Shulha HP, Jiang Y, Matevossian A, Wang J, Weng Z, et al. Developmental regulation and individual differences of neuronal H3K4me3 epigenomes in the prefrontal cortex. Proc Natl Acad Sci U S A. 2010;107:8824-8829.
99. Lister R, Mukamel EA, Nery JR, et al. Global epigenomic reconfiguration during mammalian brain development. Science. 2013;341:1237905.
100. McGowan PO, Sasaki A, D'Alessio AC, Dymov S, Labonte B, Szyf M, et al. Epigenetic regulation of the glucocorticoid receptor in human brain associates with childhood abuse. Nat Neurosci. 2009;12:342-348.
101. Labonte B, Suderman M, Maussion G, et al. Genome-wide epigenetic regulation by early-life trauma. Arch Gen Psychiatry. 2012;69:722-731.
102. Labonte B, Yerko V, Gross J, et al. Differential glucocorticoid receptor exon 1(B), 1(C), and 1(H) expression and methylation in suicide completers with a history of childhood abuse. Biol Psychiatry. 2012;72:41-48.
103. McGowan PO, Sasaki A, Huang TC, et al. Promoter-wide hypermethylation of the ribosomal RNA gene promoter in the suicide brain. PloS One. 2008;3:e2085.
104. Curley AA, Arion D, Volk DW, et al. Cortical deficits of glutamic acid decarboxylase 67 expression in schizophrenia: clinical, protein, and cell type-specific features. Am J Psychiatry. 2011;168:921-929.
105. Hyde TM, Lipska BK, Ali T, Mathew SV, Law AJ, Metitiri OE, et al. Expression of GABA signaling molecules KCC2, NKCC1, and GAD1 in cortical development and schizophrenia. J Neurosci. 2011;31:11088-11095.
106. Zhang TY, Hellstrom IC, Bagot RC, Wen X, Diorio J, Meaney MJ. Maternal care and DNA methylation of a glutamic acid decarboxylase 1 promoter in rat hippocampus. J Neurosci. 2010;30:13130-13137.
107. Mackowiak M, Bator E, Latusz J, Mordalska P, Wedzony K. Prenatal MAM administration affects histone H3 methylation in postnatal life in the rat medial prefrontal cortex. Eur Neuropsychopharmacol. 2014;24:271-289.
108. Huang HS, Akbarian S. GAD1 mRNA expression and DNA methylation in prefrontal cortex of subjects with schizophrenia. PloS One. 2007;2:e809.
109. Richetto J, Calabrese F, Riva MA, Meyer U. Prenatal immune activation induces maturation-dependent alterations in the prefrontal GABAergic transcriptome. Schizophr Bull. 2014;40:351-361.
110. Tang B, Jia H, Kast RJ, Thomas EA. Epigenetic changes at gene promoters in response to immune activation in utero. Brain Behav Immun. 2013;30:168-175.
111. Connor CM, Dincer A, Straubhaar J, Galler JR, Houston IB, Akbarian S. Maternal immune activation alters behavior in adult offspring, with subtle changes in the cortical transcriptome and epigenome. Schizophr Res. 2012;140:175-184.
112. Niwa M, Jaaro-Peled H, Tankou S, et al. Adolescent stress-induced epigenetic control of dopaminergic neurons via glucocorticoids. Science. 2013;339:335-339.
113. Satta R, Maloku E, Zhubi A, et al. Nicotine decreases DNA methyltransferase 1 expression and glutamic acid decarboxylase 67 promoter methylation in GABAergic interneurons. Proc Natl Acad Sci U S A. 2008;105:16356-16361.
114. Maloku E, Kadriu B, Zhubi A, et al. Selective alpha4beta2 nicotinic acetylcholine receptor agonists target epigenetic mechanisms in cortical GABAergic neurons. Neuropsychopharmacology. 2011;36:1366-1374.
115. Ronan JL, Wu W, Crabtree GR. From neural development to cognition: unexpected roles for chromatin. Nat Rev Genetics. 2013;14:347-359.
116. Klein CJ, Botuyan MV, Wu Y, et al. Mutations in DNMT1 cause hereditary sensory neuropathy with dementia and hearing loss. Nat Genet. 2011;43:595-600.
117. Winkelmann J, Lin L, Schormair B, et al. Mutations in DNMT1 cause autosomal dominant cerebellar ataxia, deafness and narcolepsy. Hum Mol Genet. 2012;2:2205-2210.
118. Cohen D, Lazar G, Couvert P, et al. MECP2 mutation in a boy with language disorder and schizophrenia. Am J Psychiatry. 2002;159:148-149.
119. Piton A, Gauthier J, Hamdan FF, Lafreniere RG, Yang Y, Henrion E, et al. Systematic resequencing of X-chromosome synaptic genes in autism spectrum disorder and schizophrenia. Mol Psychiatry. 2011;16:867-880.
120. Kirov G, Pocklington AJ, Holmans P, et al. De novo CNV analysis implicates specific abnormalities of postsynaptic signalling complexes in the pathogenesis of schizophrenia. Mol Psychiatry. 2012;17:142-153.
121. Lee Y, Mattai A, Long R, Rapoport JL, Gogtay N, Addington AM. Microduplications disrupting the MYT1L gene (2p25.3) are associated with schizophrenia. Psychiatr Genet. 2012;22:206-209.
122. Luo X, Huang L, Jia P, Li M, Su B, Zhao Z, et al. Protein-protein interaction and pathway analyses of top schizophrenia genes reveal schizophrenia susceptibility genes converge on common molecular networks and enrichment of nucleosome (chromatin) assembly genes in schizophrenia susceptibility loci. Schizophr Bull. 2014;40:39-49.
123. Gilman SR, Chang J, Xu B, et al. Diverse types of genetic variation converge on functional gene networks involved in schizophrenia. Nat Neurosci. 2012;15:1723-1728.
124. Cazzullo CL, Smeraldi E, Penati G. The leucocyte antigenic system HL-A as a possible genetic marker of schizophrenia. Br J Psychiatry. 1974;125:25-27.
125. Corvin A, Morris DW. Genome-wide Association studies: findings at the major histocompatibility complex locus in psychosis. Biol Psychiatry. 2014;75:276-283.
126. Sanders AR, Goring HH, Duan J, et al. Transcriptome study of differential expression in schizophrenia. Hum Mol Genet. 2013;22:5001-5014.
127. Mitchell AC, Bharadwaj R, Whittle C, et al. The genome in three dimensions: a new frontier in human brain research. Biol Psychiatry. 2014;75:961-969.
128. Weinberger D, Harrison P, eds. Schizophrenia. Third ed. Oxford, UK: Wiley-Blackwell; 2011.
129. Ibrahim HM, Tamminga CA. Schizophrenia: treatment targets beyond monoamine systems. Annu Rev Pharmacol Toxicol. 2011;51:189-209.
130. Akbarian S. Epigenetics of schizophrenia. Curr Topics Behav Neurosci. 2010;4:611-628.
131. Li J, Guo Y, Schroeder FA, et al. Dopamine D2-like antagonists induce chromatin remodeling in striatal neurons through cyclic AMP-protein kinase A and NMDA receptor signaling. J Neurochem. 2004;90:1117-1131.
132. Dong E, Nelson M, Grayson DR, Costa E, Guidotti A. Clozapine and sulpiride but not haloperidol or olanzapine activate brain DNA demethylation. Proc Natl Acad Sci U S A. 2008;105:13614-13649.
133. Schwarzenbacher R, McMullan D, Krishna SS, et al. Crystal structure of a glycerate kinase (TM1585) from Thermotoga maritima at 2.70 A resolution reveals a new fold. Proteins. 2006;65:243-248.
134. Dokmanovic M, Clarke C, Marks PA. Histone deacetylase inhibitors: overview and perspectives. Mol Cancer Res. 2007;5:981-989.
135. Hasan A, Mitchell A, Schneider A, Halene T, Akbarian S. Epigenetic dysregulation in schizophrenia: molecular and clinical aspects of histone deacetylase inhibitors. Eur Arch Psychiatry Clin Neurosci. 2013;263:273-284.
136. Sharma RP, Grayson DR, Gavin DP. Histone deactylase 1 expression is increased in the prefrontal cortex of schizophrenia subjects: analysis of the National Brain Databank microarray collection. Schizophr Res. 2008;98:111-117.
137. Narayan S, Tang B, Head SR, et al. Molecular profiles of schizophrenia in the CNS at different stages of illness. Brain Res. 2008;1239:235-248.
138. Jakovcevski M, Bharadwaj R, Straubhaar J, et al. Prefrontal cortical dysfunction after overexpression of histone deacetylase 1. Biol Psychiatry. 2013;74:696-705.
139. Morris MJ, Mahgoub M, Na ES, Pranav H, Monteggia LM. Loss of histone deacetylase 2 improves working memory and accelerates extinction learning. J Neurosci. 2013;33:6401-6411.
140. Cao P, Liang Y, Gao X, Zhao MG, Liang GB. Administration of MS-275 improves cognitive performance and reduces cell death following traumatic brain injury in rats. CNS Neurosci Ther. 2013;19:337-345.
141. Zhang ZY, Schluesener HJ. Oral administration of histone deacetylase inhibitor MS-275 ameliorates neuroinflammation and cerebral amyloidosis and improves behavior in a mouse model. J Neuropathol Exp Neurol. 2013;72:178-185.
142. Grayson DR, Kundakovic M, Sharma RP. Is there a future for histone deacetylase inhibitors in the pharmacotherapy of psychiatric disorders? Mol Pharmacol. 2010;77:126-135.
143. Schroeder FA, Lin CL, Crusio WE, Akbarian S. Antidepressant-like effects of the histone deacetylase inhibitor, sodium butyrate, in the mouse. Biol Psychiatry. 2007;62:55-64.
144. Zhu H, Huang Q, Xu H, Niu L, Zhou JN. Antidepressant-like effects of sodium butyrate in combination with estrogen in rat forced swimming test: involvement of 5-HT(1A) receptors. Behav Brain Res. 2009;196:200-206.
145. Covington HE, 3rd, Vialou VF, LaPlant Q, Ohnishi YN, Nestler EJ. Hippocampal-dependent antidepressant-like activity of histone deacetylase inhibition. Neurosci Lett. 2011;493:122-126.
146. Lin H, Geng X, Dang W, et al. Molecular mechanisms associated with the antidepressant effects of the class I histone deacetylase inhibitor MS-275 in the rat ventrolateral orbital cortex. Brain Res. 2012;1447:119-125.
147. Filippakopoulos P, Picaud S, Mangos M, et al. Histone recognition and large-scale structural analysis of the human bromodomain family. Cell. 2012;149:214-231.
148. Helin K, Dhanak D. Chromatin proteins and modifications as drug targets. Nature. 2013;502:480-488.
149. Fryland T, Elfving B, Christensen JH, Mors O, Wegener G, Borglum AD. Electroconvulsive seizures regulates the Brd1 gene in the frontal cortex and hippocampus of the adult rat. Neurosci Lett. 2012;516:110-113.